Recombinant vaccines against bluetongue virus

Area of Science:

• Veterinary Virology
• Immunology
• Vaccine Development

Background:

• Bluetongue (BT) is a significant hemorrhagic disease affecting ruminants globally, caused by bluetongue virus (BTV).
• BTV, a member of the Orbivirus genus (family Reoviridae), is transmitted by Culicoides biting midges and has numerous distinct serotypes.
• Previous live attenuated and inactivated vaccines have shown variable success, prompting renewed interest due to recent BTV outbreaks in Europe.

Purpose of the Study:

• To provide an overview of modern approaches for developing improved bluetongue virus (BTV) vaccines.
• To highlight the pursuit of safer, more efficacious, cross-reactive vaccines with differential diagnostic capabilities.
• To review various recombinant BTV vaccine prototypes and live viral vector strategies.

Main Methods:

• Review of existing literature on BTV vaccine development strategies.
• Investigation of recombinant vaccine prototypes, including baculovirus-expressed subunit vaccines.
• Exploration of live viral vector-based vaccine approaches.
• Inclusion of recent unpublished data on novel vaccine candidates.

Main Results:

• A wide array of modern vaccine development strategies for BTV are under investigation.
• Recombinant technologies and viral vectors represent promising avenues for next-generation BTV vaccines.
• Ongoing research aims to address limitations of current vaccines, focusing on enhanced safety and efficacy.

Conclusions:

• Significant advancements are being made in developing novel BTV vaccines.
• Modern approaches offer potential for improved control of bluetongue disease.
• Future vaccines are expected to provide better protection and diagnostic differentiation.